ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2016
Disease-Modifying Therapies in Multiple Sclerosis: Overview and Treatment Considerations.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Metabolomics in Multiple Sclerosis: Advances, Challenges, and Clinical Perspectives-A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Pooled it
- Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.Journal of neurology · 2024Pooled it
- Understanding lifestyle self-management regimens that improve the life quality of people living with multiple sclerosis: a systematic review and meta-analysis.Health and quality of life outcomes · 2022Pooled it
- Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression.Journal of managed care & specialty pharmacy · 2021Pooled it
- Pooled it
- Elevated Corpus Callosum T1rho Reflects Disease Burden and Structural Atrophy in Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2026Article
- Cross sectional analyses indicated that body fat distribution was not associated with performance-based and self-reported outcomes among ambulatory people with multiple sclerosis.Multiple sclerosis and related disorders · 2026Article
- Induction of Antigen-Specific Tolerance in a Multiple Sclerosis Model without Broad Immunosuppression.ACS nano · 2025Article
- Cardiorespiratory fitness does not predict longitudinal changes in manual dexterity, cognition or corticospinal excitability in multiple sclerosis.Frontiers in aging neuroscience · 2025Article
- Eyes as Windows: Unveiling Neuroinflammation in Multiple Sclerosis via Optic Neuritis and Uhthoff's Phenomenon.Diagnostics (Basel, Switzerland) · 2024Article
- ACKR3 Antagonism Enhances the Repair of Demyelinated Lesions Through Both Immunomodulatory and Remyelinating Effects.Neurochemical research · 2024Article
- Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.PLOS digital health · 2024Article
- Work Adjustments by Types of Occupations Amongst People with Multiple Sclerosis: A Survey Study.Journal of occupational rehabilitation · 2024Article
- The role of multidisciplinary MS care teams in supporting lifestyle behaviour changes to optimise brain health among people living with MS: A qualitative exploration of clinician perspectives.Health expectations : an international journal of public participation in health care and health policy · 2024Article
- Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Hyperresponsiveness of Corticoid-Resistant Th17/Tc-17 Cells to TLR-2 and TLR-4 Ligands is a Feature of Multiple Sclerosis Patients at Higher Risk of Therapy Failure.Journal of inflammation research · 2024Article
- Pyroptosis the Emerging Link Between Gut Microbiota and Multiple Sclerosis.Drug design, development and therapy · 2024Review
- An updated systematic review and meta-analysis exploring the efficacy and safety of dimethyl fumarate (DMF) for patients with multiple sclerosis (MS).BMJ neurology open · 2024Article
- The Probable Infectious Origin of Multiple Sclerosis.NeuroSci · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Controlling symptoms can slow the physical and emotional disabilities associated with multiple sclerosis and help patients attain the highest quality of life possible for as long as possible.
Identifiers
30766181PMC6366576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.